Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3

Area of Science:

• Immunology
• Structural Biology
• Biochemistry

Background:

• Decoy receptor 3 (DcR3) is a secreted receptor that binds and neutralizes tumor necrosis factor (TNF) superfamily ligands, including FasL, TL1A, and LIGHT.
• Elevated DcR3 levels in cancer patients suggest its role in immune evasion by tumor cells.
• Understanding the structural basis of DcR3-ligand interactions is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To determine the crystal structure of FasL in complex with DcR3.
• To elucidate the structural mechanisms underlying DcR3's recognition of multiple TNF ligands.
• To investigate how structural modifications of FasL affect its apoptotic activity and susceptibility to DcR3 inhibition.

Main Methods:

• X-ray crystallography to determine the FasL:DcR3 complex structure.
• Comparative structural analysis of DcR3 complexes with FasL, TL1A, and LIGHT.
• Biochemical assays to assess the apoptotic activity of modified FasL and inhibition by DcR3.

Main Results:

• The crystal structure of FasL complexed with DcR3 was determined.
• Structural comparisons reveal conserved recognition mechanisms for multiple TNF ligands by DcR3.
• The FasL:DcR3 structure provides insights into the FasL:Fas interaction interface.
• Native glycosylation or structure-inspired mutations enhance FasL's apoptotic activity by reducing aggregation.
• Recombinant DcR3 effectively inhibits the enhanced apoptotic activity of modified FasL.

Conclusions:

• DcR3 utilizes conserved structural features to bind multiple TNF ligands, contributing to immune evasion in cancer.
• The FasL:DcR3 structure offers a basis for understanding FasL-mediated apoptosis and its regulation.
• Strategies to enhance FasL activity or inhibit DcR3 could be therapeutically relevant in cancer treatment.